Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a gynecologic oncology group trial

Frederick Stehman, Brian N. Bundy, Gillian Thomas, Henry M. Keys, Gerrit D'Ablaing, Wesley C. Fowler, Rodrigue Mortel, William T. Creasman

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.

Original languageEnglish
Pages (from-to)1523-1528
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number8
StatePublished - 1993
Externally publishedYes

Fingerprint

Misonidazole
Hydroxyurea
Radiation
Carcinoma
Cervix Uteri
Radiotherapy
Leukopenia
Disease-Free Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stehman, F., Bundy, B. N., Thomas, G., Keys, H. M., D'Ablaing, G., Fowler, W. C., ... Creasman, W. T. (1993). Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a gynecologic oncology group trial. Journal of Clinical Oncology, 11(8), 1523-1528.

Hydroxyurea versus misonidazole with radiation in cervical carcinoma : Long-term follow-up of a gynecologic oncology group trial. / Stehman, Frederick; Bundy, Brian N.; Thomas, Gillian; Keys, Henry M.; D'Ablaing, Gerrit; Fowler, Wesley C.; Mortel, Rodrigue; Creasman, William T.

In: Journal of Clinical Oncology, Vol. 11, No. 8, 1993, p. 1523-1528.

Research output: Contribution to journalArticle

Stehman, F, Bundy, BN, Thomas, G, Keys, HM, D'Ablaing, G, Fowler, WC, Mortel, R & Creasman, WT 1993, 'Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a gynecologic oncology group trial', Journal of Clinical Oncology, vol. 11, no. 8, pp. 1523-1528.
Stehman, Frederick ; Bundy, Brian N. ; Thomas, Gillian ; Keys, Henry M. ; D'Ablaing, Gerrit ; Fowler, Wesley C. ; Mortel, Rodrigue ; Creasman, William T. / Hydroxyurea versus misonidazole with radiation in cervical carcinoma : Long-term follow-up of a gynecologic oncology group trial. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 8. pp. 1523-1528.
@article{cbc06fd08ed844208e4bc191fc9eb075,
title = "Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a gynecologic oncology group trial",
abstract = "Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39{\%} of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8{\%} v 33.6{\%}). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.",
author = "Frederick Stehman and Bundy, {Brian N.} and Gillian Thomas and Keys, {Henry M.} and Gerrit D'Ablaing and Fowler, {Wesley C.} and Rodrigue Mortel and Creasman, {William T.}",
year = "1993",
language = "English",
volume = "11",
pages = "1523--1528",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Hydroxyurea versus misonidazole with radiation in cervical carcinoma

T2 - Long-term follow-up of a gynecologic oncology group trial

AU - Stehman, Frederick

AU - Bundy, Brian N.

AU - Thomas, Gillian

AU - Keys, Henry M.

AU - D'Ablaing, Gerrit

AU - Fowler, Wesley C.

AU - Mortel, Rodrigue

AU - Creasman, William T.

PY - 1993

Y1 - 1993

N2 - Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.

AB - Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.

UR - http://www.scopus.com/inward/record.url?scp=0027165660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027165660&partnerID=8YFLogxK

M3 - Article

C2 - 8336190

AN - SCOPUS:0027165660

VL - 11

SP - 1523

EP - 1528

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -